It is worth mentioning that, although the BRAF biomarker is not currently listed in the catalog for the molecular study of lung cancer, it is included in the indicators, given its clinical relevance and the development of new therapies directed at this molecular target. The gene discussed is BRAF; the disease is lung cancer.